Products at a Glance 2024

www.pelobiotech.com

www.pelobiotech.com Cells & Tissues iPS Cells Induced Pluripotent Stem Cells (iPSCs) have revolutionized the field of regenerative medicine and scientific research by offering a versatile platform for studying and harnessing the potential of stem cells. These remarkable cells, pioneered by Dr. Shinya Yamanaka, are capable of differentiating into a wide range of cell types, mirroring the attributes of embryonic stem cells. We offer a wide range of reprogramming tools, recombinant proteins and small molecules for this application. Recombinant proteins, synthetic transcription factors, enhance targeted reprogramming, while small molecules, such as valproic acid, optimize efficiency and maintain pluripotency. Additionally, the choice of an appropriate coating for culture vessels such as recombinant Laminin is crucial in supporting iPSC attachment, proliferation, and differentiation. Every cell type will have a variant of integrin and thereby you will require a specific laminin for each cell type, we recommend you check out our ECM solutions i-Matrix 211, 411, 511. This integrated approach, including proper coating considerations, streamlines iPSC generation, addressing safety concerns and making them a valuable resource for scientific and regenerative applications. • Ready-to-use iPSCs crafted from different techniques such as footprint-free StemRNA 3rd Gen Reprogramming Technology, Retrovirus & Sendai virus. • No need for specialized reprogramming expertise. • Available from both males and females, complete with donor clinical status. • Sourced from skin fibroblasts and blood endothelial progenitor cells. We would like to point out to you as an interested party in genetically modified cells (e.g. iPS cells, GFP/RFP tagged cells) that you have a corresponding authorized genetic engineering facility for the storage, use and disposal in which this organism is processed. iPS cells and/or GFP/RFP expressing cells produced by infection using viruses are deemed potential hazards and are graded Biosafety Level 1. Restrictions are placed on the distribution of Biosafety Level 2 cells. Cells infected with human pathogenic viruses, or known to release human pathogenic viruses may be distributed only to customers who provide evidence that they have the necessary authorization to work with pathogens. In Germany, a permit according to §44 Infektionsschutzgesetz (IfSG) must be provided. For exceptions, see §45 IfSG. Customers from outside Germany must show a valid permit provided by their competent authorities. PELOBiotech GmbH reserves the right to decline the shipment of Biosafety Level 2 cells. 8

www.pelobiotech.com GMP iPS cells GMP iPSCs are high-quality induced pluripotent stem cells derived from adult tissue biopsies, suitable for therapeutic applications. They meet strict regulatory standards to ensure their safety and effectiveness for human use. • We use StemRNA Reprogramming Technology, which is virus-free and complies with regulatory guidelines. • Benefits include iPSCs manufactured according to ICH 5QA standards, generated with footprint-free RNA reprogramming technology, and available for commercial use. • Diverse donors and over 30 years of experience in human tissue procurement. • StemRNA Reprogramming Technology produces robust iPSCs with low batch-to-batch variation, eliminating the need for screening exogenous genes. • Our iPSC seed stocks, Master Cell Banks, and working cell banks are suitable for commercial and therapeutic applications. iPS derived cells We use human iPSC technology, to create a wide range of cell models and biosensor technologies. Our capabilities cater to various applications, spanning preclinical drug discovery, biobanking, in vitro diagnostics, and biomarker development. Induced pluripotent stem (iPS) cells offer several advantages and serve as a superior human disease model compared to animal cells for several reasons: • Human Relevance: iPS cells are derived from human tissues, making them more relevant for studying human diseases. This is crucial because human physiology and disease mechanisms can differ significantly from those of animals. • Patient-Specific Modeling: iPS cells can be generated from individual patients, allowing the creation of patientspecific disease models. This is invaluable for studying genetic diseases and understanding the unique aspects of a patient's condition. • Disease Recapitulation: iPS cells can be differentiated into a variety of cell types relevant to the disease being studied, such as neurons, cardiomyocytes, or hepatocytes. This enables researchers to closely mimic disease conditions in a dish. • Genetic Manipulation: iPS cells can be genetically modified to introduce disease-associated mutations or correct genetic defects. This provides a precise way to investigate the genetic basis of diseases. • Drug Screening: iPS-derived cells can be used for high-throughput drug screening to identify potential therapies or test drug efficacy. This is particularly important for personalized medicine. • Reduced Ethical Concerns: Using iPS cells alleviates many ethical concerns associated with the use of embryonic stem cells, which can be controversial. • Consistency: iPS cells provide a consistent and reproducible source of human cells for experimentation, eliminating genetic variability found in animal models. • Translation to Clinical Applications: iPS cells have the potential to be used in cell-based therapies and regenerative medicine, making them a bridge between research and clinical applications. • Longitudinal Studies: Researchers can derive iPS cells from patients at different stages of a disease and track the disease progression over time, which is challenging to do with animal models. • Cost and Time Efficiency: iPS cell-based research is often more cost-effective and less time-consuming than working with animal models. The latest applications of induced pluripotent stem cells (iPSCs) encompass a wide array of cutting-edge advancements in regenerative medicine, disease modeling, drug screening, and cell therapy. These applications have been made possible by the unique properties of iPSCs, which are similar to embryonic stem cells (ESCs) in terms of morphology, proliferation, and gene expression profile (Okita & Yamanaka, 2008). iPSC technology has significantly enriched regenerative medicine by introducing autologous pluripotent progenitor pools bioengineered from ordinary somatic tissue, offering potential in disease modeling and therapeutic applications (Nelson et al., 2009; Polo et al., 2010). Notably, the first clinical study using human iPSC-derived cells was initiated in 2014, utilizing human iPSC-derived retinal pigment epithelial (RPE) cells to treat macular degeneration, resulting in improved vision for the patient (Shi et al., 2016). Recent advances in differentiating cells such as cardiac, neural, and skeletal muscle cells from iPSCs, as well as directly reprogramming somatic cells in tissue regeneration applications, have been summarized and synthesized, highlighting the versatility of iPSCs in various therapeutic contexts (Mao et al., 2022). iPSCs have also been explored for bone regeneration, cardiovascular disease, and as pre-clinical models for studying human disease, demonstrating their potential in diverse medical applications (He et al., 2018; Plews et al., 2012; Huang et al., 2020). 9